Apple
AAPL
Oracle
ORCL
Adobe
ADBE
Ecopetrol
EC
D.R. Horton
DHI
US Stock MarketDetailed Quotes
CVKD Cadrenal Therapeutics
- 12.960
- +1.510+13.19%
Close Dec 18 16:00 ET
- 13.780
- +0.820+6.33%
Pre 08:54 ET
21.50MMarket Cap-2.10P/E (TTM)
13.860High11.080Low122.23KVolume11.570Open11.450Pre Close1.56MTurnover11.18%Turnover RatioLossP/E (Static)1.66MShares32.55052wk High6.30P/B14.18MFloat Cap5.40052wk Low--Dividend TTM1.09MShs Float101.250Historical High--Div YieldTTM24.28%Amplitude5.400Historical Low12.759Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Cadrenal Therapeutics Stock Forum
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation th...
Larger Image: tradingview.com...
$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. T...
No comment yet